J&J Tops Q2 Forecasts and Lifts 2026 Outlook on Robust Drug Sales
JNJ sits 61% above its 52-week low of $154.8.
Summary
Johnson & Johnson posted Q2 2026 sales of $25.31B and adjusted EPS of $2.90, exceeding consensus, and lifted full-year guidance to $101.1B in revenue and $11.68 in adjusted EPS.
Key Events · Earnings and Guidance · JNJ
-
Q2 Beat Across the Board
Driven by oncology and immunology, sales of $25.31B grew 6.6% on a reported basis (5.6% operationally), while adjusted EPS of $2.90 rose 4.7% year-over-year.
-
Full-Year Guidance Raised
Reflecting confidence in the pipeline and commercial execution, the 2026 reported sales midpoint was raised to $101.1B (7.3% growth) and the adjusted EPS midpoint to $11.68 (8.2% growth).
-
Oncology and Immunology Drive Growth
DARZALEX sales hit $4.2B (+18.9%), CARVYKTI reached $657M (+49.4%), and TREMFYA surged to $2.0B (+72.5%), more than offsetting STELARA's 55.2% decline to $740M.
-
Strong Cash Generation
First-half 2026 free cash flow is estimated at ~$8.7B, up from $6.2B in the prior year, providing ample capacity for investment and shareholder returns.
Analysis · JNJ · Life Sciences
A clean beat on both revenue and earnings highlighted Johnson & Johnson's second quarter, with sales reaching $25.31 billion and adjusted EPS coming in at $2.90. Bolstered by that performance, management raised full-year 2026 guidance—the new midpoint for reported sales stands at $101.1 billion, marking the first time in the company's 140-year history that annual revenue crosses the $100 billion threshold. The upward revision reflects strength in oncology (DARZALEX, CARVYKTI) and immunology (TREMFYA), which more than compensated for ongoing STELARA erosion from biosimilars. Underpinning the pipeline and capital allocation is roughly $8.7 billion in free cash flow generated during the first half.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JNJ was trading at $248.86 on NYSE in the Life Sciences sector, with a market capitalization of approximately $611.1B. The 52-week trading range was $154.80 to $269.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.